492 related articles for article (PubMed ID: 17003449)
1. Delivery from episcleral exoplants.
Pontes de Carvalho RA; Krausse ML; Murphree AL; Schmitt EE; Campochiaro PA; Maumenee IH
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4532-9. PubMed ID: 17003449
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry.
Ghate D; Brooks W; McCarey BE; Edelhauser HF
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2230-7. PubMed ID: 17460284
[TBL] [Abstract][Full Text] [Related]
3. Ocular tissue distribution of betamethasone after anterior-episcleral, posterior-episcleral, and anterior-intrascleral placement of nonbiodegradable implants.
Okabe K; Kimura H; Okabe J; Ogura Y
Retina; 2007; 27(6):770-7. PubMed ID: 17621189
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of intraocular drug delivery of Oregon green 488-labeled triamcinolone by subtenon injection using ocular fluorophotometry in rabbit eyes.
Lee SJ; Kim ES; Geroski DH; McCarey BE; Edelhauser HF
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4506-14. PubMed ID: 18503001
[TBL] [Abstract][Full Text] [Related]
5. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging.
Kim H; Robinson MR; Lizak MJ; Tansey G; Lutz RJ; Yuan P; Wang NS; Csaky KG
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2722-31. PubMed ID: 15277497
[TBL] [Abstract][Full Text] [Related]
6. In vivo ocular fluorophotometry: delivery of fluoresceinated dextrans via transscleral diffusion in rabbits.
Berezovsky DE; Patel SR; McCarey BE; Edelhauser HF
Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7038-45. PubMed ID: 21791594
[TBL] [Abstract][Full Text] [Related]
7. Episcleral implants for topotecan delivery to the posterior segment of the eye.
Carcaboso AM; Chiappetta DA; Opezzo JA; Höcht C; Fandiño AC; Croxatto JO; Rubio MC; Sosnik A; Abramson DH; Bramuglia GF; Chantada GL
Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):2126-34. PubMed ID: 19834044
[TBL] [Abstract][Full Text] [Related]
8. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide.
Robinson MR; Lee SS; Kim H; Kim S; Lutz RJ; Galban C; Bungay PM; Yuan P; Wang NS; Kim J; Csaky KG
Exp Eye Res; 2006 Mar; 82(3):479-87. PubMed ID: 16168412
[TBL] [Abstract][Full Text] [Related]
9. Effect of intraocular pressure (IOP) and choroidal circulation on controlled episcleral drug delivery to retina/vitreous.
Li J; Lan B; Li X; Sun S; Lu P; Cheng L
J Control Release; 2016 Dec; 243():78-85. PubMed ID: 27717742
[TBL] [Abstract][Full Text] [Related]
10. Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels.
Behar-Cohen FF; El Aouni A; Gautier S; David G; Davis J; Chapon P; Parel JM
Exp Eye Res; 2002 Jan; 74(1):51-9. PubMed ID: 11878818
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant.
Kato A; Kimura H; Okabe K; Okabe J; Kunou N; Ogura Y
Invest Ophthalmol Vis Sci; 2004 Jan; 45(1):238-44. PubMed ID: 14691179
[TBL] [Abstract][Full Text] [Related]
12. Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy.
Carcaboso AM; Bramuglia GF; Chantada GL; Fandiño AC; Chiappetta DA; de Davila MT; Rubio MC; Abramson DH
Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3761-7. PubMed ID: 17652749
[TBL] [Abstract][Full Text] [Related]
13. Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry.
Tyagi P; Kadam RS; Kompella UB
PLoS One; 2012; 7(10):e48188. PubMed ID: 23118950
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate delivery to the eye using transscleral hydrogel iontophoresis.
Eljarrat-Binstock E; Domb AJ; Orucov F; Frucht-Pery J; Pe'er J
Curr Eye Res; 2007; 32(7-8):639-46. PubMed ID: 17852187
[TBL] [Abstract][Full Text] [Related]
15. In vitro sustained human transscleral drug delivery of fluorescein-labeled dexamethasone and methotrexate with fibrin sealant.
Cruysberg LP; Nuijts RM; Gilbert JA; Geroski DH; Hendrikse F; Edelhauser HF
Curr Eye Res; 2005 Aug; 30(8):653-60. PubMed ID: 16109645
[TBL] [Abstract][Full Text] [Related]
16. Effects of acetazolamide on passive and active transport of fluorescein across the normal BRB.
Moldow B; Sander B; Larsen M; Lund-Andersen H
Invest Ophthalmol Vis Sci; 1999 Jul; 40(8):1770-5. PubMed ID: 10393047
[TBL] [Abstract][Full Text] [Related]
17. Ocular pharmacokinetics in rabbits using a novel dual probe microdialysis technique.
Macha S; Mitra AK
Exp Eye Res; 2001 Mar; 72(3):289-99. PubMed ID: 11180978
[TBL] [Abstract][Full Text] [Related]
18. Ocular fluorescein kinetics before and after vitrectomy on swine.
Knudsen LL; Dissing T; Hansen MN; Nielsen-Kudsk F
Graefes Arch Clin Exp Ophthalmol; 2001 Nov; 239(11):832-9. PubMed ID: 11789863
[TBL] [Abstract][Full Text] [Related]
19. Transscleral delivery of bioactive protein to the choroid and retina.
Ambati J; Gragoudas ES; Miller JW; You TT; Miyamoto K; Delori FC; Adamis AP
Invest Ophthalmol Vis Sci; 2000 Apr; 41(5):1186-91. PubMed ID: 10752959
[TBL] [Abstract][Full Text] [Related]
20. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling.
Ranta VP; Urtti A
Adv Drug Deliv Rev; 2006 Nov; 58(11):1164-81. PubMed ID: 17069929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
